ES2176288T3 - Compuestos de 2-(4-hidroxifenil)benzotiofeno, composiciones y procedimientos para alivir el sindrome postmenopausico. - Google Patents
Compuestos de 2-(4-hidroxifenil)benzotiofeno, composiciones y procedimientos para alivir el sindrome postmenopausico.Info
- Publication number
- ES2176288T3 ES2176288T3 ES95306540T ES95306540T ES2176288T3 ES 2176288 T3 ES2176288 T3 ES 2176288T3 ES 95306540 T ES95306540 T ES 95306540T ES 95306540 T ES95306540 T ES 95306540T ES 2176288 T3 ES2176288 T3 ES 2176288T3
- Authority
- ES
- Spain
- Prior art keywords
- alkilo
- formula
- pirrolidinyl
- compounds
- benzotiophene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA NUEVOS COMPUESTOS DE BENZOTIOFENO DE FORMULA I EN DONDE R ES -H, -OH, -O(ALKILO C1-C4), -O-CO-(ALKILO C1-C6), -O-CO-AR EN EL QUE AR ES FENILO OPCIONALMENTE SUSTITUIDO, O -O-SO2-(ALKILO C4C6); R1 ES -H, -OH, -O(ALKILO C1-C4), -O-CO(ALKILO C1-C6), -O-CO-AR EN EL QUE AR ES FENILO OPCIONALMENTE SUSTITUIDO, -O-SO2-(ALKILO C4-C6) CLORO O BROMO; R2} ES -H O -OH; N ES 2 O 3; Y R3 Y R4 SON CADA UNO INDEPENDIENTEMENTE ALKILO C1-C4, O SE COMBINAN PARA FORMAR 1-PIPERIDINILO, 1PIRROLIDINO, METILO-1-PIRROLIDINILO, DIMETILO-L-PIRROLIDINILO, 4-MORFOLINO, O 1-HEXAMETILENEIMINO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS. ADEMAS SE PROPORCIONAN METODOS PARA ALIVIAR LOS SINTOMAS DEL SINDROME POST-MENOPAUSIA, E INHIBICION DE ENDOMETRIOSIS, FIBROSIS UTERINA, Y PROLIFERACION CELULAR DEL MUSCULO BLANDO. ADEMAS SE PROPORCIONAN FORMULACIONES FARMACEUTICAS CON COMPUESTOS DE FORMULA I, QUE INCLUYEN OPCIONALMENTE ESTROGENO O PROGESTINA. LA PRESENTE INVENCION PROPORCIONA ADEMAS UN PROCESO PARA PREPARAR UN COMPUESTO DE FORMULA IC EN DONDE RA Y R1A SON -OH O -OR5; R3 Y R4 SON CADA UNO INDEPENDIENTEMENTE ALKILO C1-C4, O COMBINAN PARA FORMAR 1-PIPERIDINILO, 1PIRROLIDINO, METILO-1-PIRROLIDINILO, DIMETILO-L-PIRROLIDINILO, 4-MORFOLINO, O 1-HEXAMETILENEIMINO; Y R5 ES UN GRUPO DE PROTECCION HIDROXI CAPAZ DE RESISTIR LA REDUCCION MEDIANTE UN AGENTE DE REDUCCION FUERTE; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, QUE COMPRENDE: A) LA ELIMINACION OPCIONALMENTE DE LOS GRUPOS DE PROTECCION HIDROXI R5 DE UN COMPUESTO DE FORMULA II EN DONDE N, R3, R4, Y R5 SON COMO SE HA DEFINIDO ANTERIORMENTE, O UNA SAL DE LOS MISMOS; B) LA REACCION DE DICHO COMPUESTO DE FORMULA II CON UN AGENTE DE REDUCCION EN LA PRESENCIA DE UN DISOLVENTE QUE TIENE UN PUNTO DE EBULLICION EN EL RANGO DE ALREDEDOR DE 150 (GRADOS) C A ALREDEDOR DE 200ºC, Y CALENTAMIENTO DE LA MEZCLA DE REFLUJO; Y C) SALIFICACION OPCIONALMENTE DEL PRODUCTO DE REACCION DEL PASO B).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30930194A | 1994-09-20 | 1994-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2176288T3 true ES2176288T3 (es) | 2002-12-01 |
Family
ID=23197619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95306540T Expired - Lifetime ES2176288T3 (es) | 1994-09-20 | 1995-09-18 | Compuestos de 2-(4-hidroxifenil)benzotiofeno, composiciones y procedimientos para alivir el sindrome postmenopausico. |
Country Status (8)
Country | Link |
---|---|
US (3) | US6399634B1 (es) |
EP (1) | EP0703231B1 (es) |
JP (1) | JPH10506112A (es) |
AU (1) | AU3686495A (es) |
CA (1) | CA2200204A1 (es) |
DE (1) | DE69526550T2 (es) |
ES (1) | ES2176288T3 (es) |
WO (1) | WO1996009041A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
CA2162586C (en) | 1993-05-13 | 2006-01-03 | David J. Grainger | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US6703407B1 (en) * | 1994-09-20 | 2004-03-09 | Eli Lilly And Company | Benzofuran compounds, compositions, and methods |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5856339A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
SG90193A1 (en) * | 1995-02-28 | 2002-07-23 | Lilly Co Eli | Benzothiophene compounds, intermediates, compositions, and methods |
US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
US6417199B1 (en) * | 1995-03-10 | 2002-07-09 | Eli Lilly And Company | 3-benzyl-benzothiophenes |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
JPH11510479A (ja) | 1995-06-07 | 1999-09-14 | ネオルックス コーポレイション | タモキシフェン類似体による心臓血管疾病の予防及び治療 |
EP0747380B1 (en) * | 1995-06-07 | 1998-09-30 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side chains |
US5728724A (en) * | 1995-08-17 | 1998-03-17 | Eli Lilly And Company | Benzothiophene compounds |
US6432982B1 (en) | 1996-02-21 | 2002-08-13 | Eli Lilly And Company | Benzothiophenes, and formulations and methods using same |
IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
CA2206752A1 (en) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
CA2213810C (en) * | 1996-08-29 | 2006-06-06 | Lewis Dale Pennington | Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods |
CA2213814A1 (en) * | 1996-08-29 | 1998-02-28 | Henry Uhlman Bryant | Naphthalene compounds, intermediates, formulations, and methods |
CA2214072C (en) * | 1996-08-29 | 2006-11-14 | Eli Lilly And Company | Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods |
CA2214919A1 (en) * | 1996-09-24 | 1998-03-24 | Kenneth Lee Hauser | Benzothiophene compounds, intermediates, processes, compositions, and methods |
CA2214176A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Dihydrobenzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods |
CA2214196A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods |
US5948796A (en) * | 1996-10-10 | 1999-09-07 | Eli Lilly And Company | Benzo B!thiophene compounds, intermediates, formulations, and methods |
CA2214872C (en) * | 1996-10-24 | 2002-01-22 | Eli Lilly And Company | Benzothiophene compounds, compositions and methods |
JPH10204082A (ja) * | 1996-10-25 | 1998-08-04 | Eli Lilly & Co | 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ[b]チオフェン化合物 |
US5760030A (en) * | 1997-06-30 | 1998-06-02 | Eli Lilly And Company | Benzothiophene compounds and methods of use |
US6017914A (en) * | 1997-09-03 | 2000-01-25 | Eli Lilly And Company | Benzo[b]thiophene compounds, intermediates, formulations, and methods |
EP1067839A1 (en) * | 1998-04-08 | 2001-01-17 | Eli Lilly And Company | Pulmonary and nasal delivery of raloxifene |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
KR20010101931A (ko) | 1999-02-03 | 2001-11-15 | 피터 지. 스트링거 | α1-아드레날린성 수용체 길항제 |
US8076063B2 (en) * | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
US7611869B2 (en) * | 2000-02-07 | 2009-11-03 | Illumina, Inc. | Multiplexed methylation detection methods |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
CA2444787A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
DE60210283T2 (de) | 2001-05-22 | 2006-11-09 | Eli Lilly And Co., Indianapolis | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
US7399867B2 (en) | 2002-07-22 | 2008-07-15 | Eli Lilly And Company | Selective estrogen receptor modulators containing a phenylsulfonyl group |
AU2004216258B2 (en) | 2003-02-25 | 2006-10-19 | Eli Lilly And Company | Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
US20070066595A1 (en) | 2004-01-22 | 2007-03-22 | Dodge Jeffrey A | Selective estrogen receptor modulators |
GR1005694B (el) * | 2005-06-08 | 2007-10-22 | Αλεξης Μιχαηλ | Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων |
US7655700B2 (en) | 2005-08-25 | 2010-02-02 | Michigan State University | Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
EP1945182B1 (en) * | 2005-10-14 | 2010-07-28 | Janssen Pharmaceutica N.V. | Formulations of tipifarnib for intravenous application |
KR20150039882A (ko) | 2010-06-16 | 2015-04-13 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3396169A (en) * | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
US3862232A (en) * | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
US3313853A (en) * | 1963-10-16 | 1967-04-11 | Upjohn Co | 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones |
US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
US3320271A (en) | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
GB1138163A (en) * | 1965-05-21 | 1968-12-27 | Bristol Myers Co | Benzothiophene derivatives having anti-fertility properties |
US3394125A (en) | 1965-10-23 | 1968-07-23 | Bristol Myers Co | 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group |
US3483293A (en) * | 1967-12-15 | 1969-12-09 | Upjohn Co | Method for controlling birds and rodents |
US3567737A (en) * | 1968-01-02 | 1971-03-02 | Upjohn Co | Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes |
US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
NZ200204A (en) * | 1981-04-03 | 1985-05-31 | Lilly Co Eli | Benzothiophene derivatives and process for preparation |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4358593A (en) | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4380645A (en) * | 1981-12-11 | 1983-04-19 | Merck & Co., Inc. | Process for preparing Benzoxepino- or Benzthiapino[4,3-b]pyrrole-2-acetic acids |
GB8311678D0 (en) * | 1983-04-28 | 1983-06-02 | Ici Plc | Phenol derivatives |
US4851554A (en) * | 1987-04-06 | 1989-07-25 | University Of Tennessee Research Corporation | Certain 3-substituted 2-alkyl benzofuran derivatives |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5254568A (en) | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
DE4117512A1 (de) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
US5384332A (en) * | 1994-05-11 | 1995-01-24 | Eli Lilly And Company | Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives |
-
1995
- 1995-04-19 US US08/423,498 patent/US6399634B1/en not_active Expired - Fee Related
- 1995-04-19 US US08/424,989 patent/US5484798A/en not_active Expired - Fee Related
- 1995-04-19 US US08/424,988 patent/US5492921A/en not_active Expired - Fee Related
- 1995-09-18 CA CA002200204A patent/CA2200204A1/en not_active Abandoned
- 1995-09-18 WO PCT/US1995/012350 patent/WO1996009041A1/en active Search and Examination
- 1995-09-18 JP JP8511135A patent/JPH10506112A/ja not_active Ceased
- 1995-09-18 DE DE69526550T patent/DE69526550T2/de not_active Expired - Fee Related
- 1995-09-18 EP EP95306540A patent/EP0703231B1/en not_active Expired - Lifetime
- 1995-09-18 AU AU36864/95A patent/AU3686495A/en not_active Abandoned
- 1995-09-18 ES ES95306540T patent/ES2176288T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2200204A1 (en) | 1996-03-28 |
AU3686495A (en) | 1996-04-09 |
DE69526550D1 (de) | 2002-06-06 |
DE69526550T2 (de) | 2002-10-31 |
US5484798A (en) | 1996-01-16 |
US5492921A (en) | 1996-02-20 |
EP0703231A1 (en) | 1996-03-27 |
WO1996009041A1 (en) | 1996-03-28 |
EP0703231B1 (en) | 2002-05-02 |
JPH10506112A (ja) | 1998-06-16 |
US6399634B1 (en) | 2002-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2176288T3 (es) | Compuestos de 2-(4-hidroxifenil)benzotiofeno, composiciones y procedimientos para alivir el sindrome postmenopausico. | |
AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
ES2100302T3 (es) | Procedimiento para la fabricacion de composiciones de poliuretano cationico y sales de amonio cuaternario. | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
AR035497A1 (es) | Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos | |
AR002964A1 (es) | Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento. | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR029150A1 (es) | Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende. | |
UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
CO5180642A1 (es) | Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion | |
AR039673A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion | |
AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
AR023574A1 (es) | Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios | |
KR830006174A (ko) | 기관지 항경련성 화합물 제조방법 | |
HUP0402225A2 (hu) | Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
UY29869A1 (es) | Compuestos de benzamida | |
KR940701264A (ko) | 안과질환에 대한 마크로라이드 화합물의 용도 | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
AR056613A1 (es) | Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen | |
ES2095942T3 (es) | Derivados de bencenoacetamida inhibidores del vih. | |
GB1046506A (en) | Guanidine compounds and process for their manufacture | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. |